Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome.
暂无分享,去创建一个
S. Dusza | T. Kuzel | C. Querfeld | J. Guitart | S. Rosen | M. Duvic | Youn H. Kim
[1] I. Lossos,et al. Single‐agent lenalidomide is active in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma who received prior stem cell transplantation , 2013, British journal of haematology.
[2] B. Coiffier,et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. , 2013, European journal of cancer.
[3] Bo Yang,et al. Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2013, PloS one.
[4] B. Coiffier,et al. Lenalidomide in Diffuse Large B-Cell Lymphoma , 2012, Advances in hematology.
[5] A. Tsimberidou,et al. Lenalidomide in solid tumors , 2012, Cancer Chemotherapy and Pharmacology.
[6] M. Beksac,et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.
[7] D. Fisher,et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2012, Blood.
[8] A. Pinto,et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response , 2012, Cancer.
[9] M. Czuczman,et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response , 2012, Cancer.
[10] M. Czuczman,et al. Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response , 2011, British journal of haematology.
[11] M. Cazzola,et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.
[12] J. Scarisbrick,et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Becker,et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] W. Sterry,et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Vose,et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Steinberg,et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Verma,et al. Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.
[18] S. Devesa,et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.
[19] I. Lossos,et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma , 2009, British journal of haematology.
[20] I. Lossos,et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Pulini,et al. Prognostic markers in mycosis fungoides. , 2008, Analytical and quantitative cytology and histology.
[22] A. J. Wilson,et al. Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides , 2008, Clinical Cancer Research.
[23] K. Rossen,et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival , 2007, Leukemia.
[24] M. Weinstock,et al. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. , 2007, Archives of dermatology.
[25] T. Illidge,et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. , 2007, Blood.
[26] M. Czuczman,et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Whittaker,et al. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. , 2006, The Journal of investigative dermatology.
[28] Nicola Pimpinelli,et al. WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.
[29] Angus G. Dalgleish,et al. The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.
[30] G. Juliusson,et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. , 2003, Blood.
[31] M. Duvic,et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] G. Wood,et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.
[33] J. Chmiel,et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting , 2001, Journal of cutaneous pathology.
[34] S. Steinberg,et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. , 1989, The New England journal of medicine.
[35] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[36] J. Becker,et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. , 2013, European journal of cancer.
[37] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.
[38] M. Gordon. Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .